MedTrace Logo

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

NCT06271512 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-02-11

No results posted yet for this study

Summary

The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.

Conditions

Interventions

OTHER

No Intervention

This is non-interventional study.

Sponsors & Collaborators

Principal Investigators

  • Himal Lal Thakar, MD · bluebird bio, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2043-12-31
Completion
2043-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06271512 on ClinicalTrials.gov